EMA Recommends 12 New Medicines for Approval
The European Medicines Agency’s (EMA) human medicines committee has recommended 12 new medications for marketing authorization in the European Union. Highlights from the February meeting include a new treatment for pediatric low-grade glioma and several other innovative therapies for chronic conditions. These recommendations now proceed to the European Commission for final approval, which will allow the drugs to be marketed across all EU member states. This batch of recommendations represents a significant step forward in providing patients with advanced treatment options. The agency continues to prioritize high safety standards while accelerating access to life-saving innovation.
EU patients will soon have access to 12 new treatments, including pediatric cancer therapies.